Evaluation of macrophage-specific promoters using lentiviral delivery in mice

Gene Therapy

Volumn 19, Issue 11, 2012, Pages 1041-1047

  Levin, M C ^a   Lidberg, U ^a   Jirholt, P ^b   Adiels, M ^a   Wramstedt, A ^a   Gustafsson, K ^c   Greaves, D R ^d   Li, S ^e   Fazio, S ^f   Linton, M F ^f   Olofsson, S O ^a   Boren J ^a   Gjertsson, I ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Mays Cancer Center at UT Health San Antonio   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lentivirus; Macrophage; Promoter

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; GLYCOPROTEIN P 15095; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL POPULATION; CONTROLLED STUDY; EVALUATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE; GENE DOSAGE; GENE EXPRESSION; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; MACROPHAGES; MICE; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; TRANSDUCTION, GENETIC; TRANSGENES;

LENTIVIRUS; MUS;

EID: 84869092003     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.195     Document Type: Article

References (29)

1. Toscano MG, Romero Z, Munoz P, Cobo M, Benabdellah K, Martin F. Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Therapy 2010; 18: 117-127.
2. Janeway C, Travers P, Walport M, Shlomchik M. Immunobiology, the Immune System in Health and Disease. Garland Publishing: Garland Science, New York, NY, USA, 2001.
3. Gierut A, Perlman H, Pope RM. Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am 2010; 36: 271-296.
4. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219: 187-203. (Pubitemid 47390007)
5. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008; 27: 11-18.
6. Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008; 222: 145-154. (Pubitemid 351430362)
7. Gough PJ, Raines EW. Gene therapy of Apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood 2003; 101: 485-491. (Pubitemid 36077569)
8. O'Reilly D, Quinn CM, El-Shanawany T, Gordon S, Greaves DR. Multiple ets factors and interferon regulatory factor-4 modulate CD68 expression in a cell typespecific manner. J Biol Chem 2003; 278: 21909-21919. (Pubitemid 36792598)
9. Su YR, Ishiguro H, Major AS, Dove DE, Zhang W, Hasty AH et al. Macrophage apolipoprotein A1 expression protects against atherosclerosis in ApoE-deficient mice and upregulates ABC transporters. Mol Ther 2003; 8: 576-583. (Pubitemid 37321686)
10. Li AC, Guidez FR, Collier JG, Glass CK. The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between pu.1 and c-jun. J Biol Chem 1998; 273: 5389-5399. (Pubitemid 28108708)
11. Horvai A, Palinski W, Wu H, Moulton KS, Kalla K, Glass CK. Scavenger receptor a gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci USA 1995; 92: 5391-5395.
12. Dziennis S, Van Etten RA, Pahl HL, Morris DL, Rothstein TL et al. The CD11b promoter directs high-level expression of reporter genes in macrophages in transgenic mice. Blood 1995; 85: 319-329.
13. Hahn CN, del Pilar Martin M, Zhou XY, Mann LW, d'Azzo A. Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin a under control of the colony-stimulating factor-1 receptor promoter. Proc Natl Acad Sci USA 1998; 95: 14880-14885. (Pubitemid 29003725)
14. Whitman SC, Rateri DL, Szilvassy SJ, Cornicelli JA, Daugherty A. Macrophagespecific expression of class A scavenger receptors in LDL receptor(-/-) mice decreases atherosclerosis and changes spleen morphology. J Lipid Res 2002; 43: 1201-1208.
15. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96: 2170-2179.
16. He W, Qiang M, Ma W, Valente AJ, Quinones MP, Wang W et al. Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther 2006; 17: 949-959. (Pubitemid 46076755)
17. Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Muller A et al. Expression of CD68 in non-myeloid cell types. Scand J Immunol 2008; 67: 453-463. (Pubitemid 351519391)
18. Greaves DR, Quinn CM, Seldin MF, Gordon S. Functional comparison of the murine macrosialin and human CD68 promoters in macrophage and nonmacrophage cell lines. Genomics 1998; 54: 165-168. (Pubitemid 28536208)
19. Coffin J, Hughes SH, Varmus HE. Retroviruses. Cold Spring Harbor Laboratory Press: Woodbury, NY, USA, 1997.
20. Su YR, Blakemore JL, Zhang Y, Linton MF, Fazio S. Lentiviral transduction of ApoA1 into hematopoietic progenitor cells and macrophages: applications to cell therapy of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1439-1446.
21. Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, Stanley ER et al. Pu.1 and c/ebpalpha/beta convert fibroblasts into macrophage-like cells. Proc Natl Acad Sci USA 2008; 105: 6057-6062. (Pubitemid 351758398)
22. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90: 489-519. (Pubitemid 27299089)
23. Lemiale F, Korokhov N. Lentiviral vectors for hiv disease prevention and treatment. Vaccine 2009; 27: 3443-3449.
24. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al. Transfusion independence and hmga2 activation after gene therapy of human betathalassaemia. Nature 2010; 467: 318-322.
25. Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010; 62: 33-40.
26. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813. (Pubitemid 34493974)
27. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892. (Pubitemid 29135675)
28. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004; 4: 648-655. (Pubitemid 39025050)
29. Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, Gross DA et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in wasp knockout mice. Gene Therapy 2005; 12: 597-606. (Pubitemid 40468107)